Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?
Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how?
复制标题
DOI：
10.1102/1470-7330.2010.9032
复制
发表时间：
2010-10-04
期刊：
影响因子：
--
通讯作者：
Koh DM
中科院分区：
文献类型：
--
作者：
Afaq A;Andreou A;Koh DM
扩散加权磁共振成像（DWI）越来越多地用于评估肿瘤对各种抗癌治疗的反应。该技术是快速执行，而不需要管理的外源性造影剂，并使组织的表观扩散系数（ADC）进行量化。研究表明，ADC增加响应于各种治疗，包括化疗、放疗、微创治疗和新型治疗。在这篇文章中，我们回顾了应用DWI进行肿瘤评估的基本原理，ADC测量与特定治疗相关的证据以及使用ADC评估治疗反应的一些实际考虑因素。
Diffusion-weighted magnetic resonance imaging (DWI) is increasingly being used to assess tumour response to a variety of anticancer treatments. The technique is quick to perform without the need for administration of exogenous contrast medium, and enables the apparent diffusion coefficient (ADC) of tissues to be quantified. Studies have shown that ADC increases in response to a variety of treatments including chemotherapy, radiotherapy, minimally invasive therapies and novel therapeutics. In this article, we review the rationale of applying DWI for tumour assessment, the evidence for ADC measurements in relation to specific treatments and some of the practical considerations for using ADC to evaluate treatment response.